Protocol Ledger

NCT07371585 · Phase II · RECRUITING

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Interventional Phase II clinical trial protocol NCT07371585 sponsored by SOLTI Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-18 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07371585
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07371585
Protocol FieldVerified Registry Value
NCT IdentifierNCT07371585
Consolidated Lead SponsorSOLTI Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2026-02-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07371585
Hospital Research SiteLocationSite Profile
Gustave RoussyVillejuif, FranceOpen Hospital Dossier ->
Hospital Clínic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI